Valeant Parkinson’s Treatment Zelapar “Approvable” For Second Time
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s latest letter on the orally disintegrating selegiline product “requests additional clarification on specific issues previously addressed by Valeant,” the company says.
You may also be interested in...
Selegiline Approved For Parkinson’s In Orally Disintegrating Tablet Form
Valeant’s Zelapar clears FDA after two “approvable” letters.
Selegiline Approved For Parkinson’s In Orally Disintegrating Tablet Form
Valeant’s Zelapar clears FDA after two “approvable” letters.
Teva Parkinson's Agent Azilect Will Launch Within 10 Weeks
Partner Eisai will continue to co-develop the MAO-B inhibitor for Alzheimer's disease, but it is "still considering" whether it will opt to co-promote the agent for Parkinson's.